Table I.
Clinicopathological features.
| Parameters | Patients, n |
|---|---|
| Sex | |
| Men | 138 |
| Women | 49 |
| Urine cytology | |
| ≥IIIb | 116 |
| ≤IIIa | 71 |
| Histology | |
| UC + differentiation | 38 |
| UC alone | 149 |
| Pathological T stage | |
| ≥T3 | 91 |
| ≤T2 | 96 |
| Tumor grade | |
| High | 132 |
| PUNLMP/low | 55 |
| Lympho node metastasis | |
| Positive | 15 |
| Negative | 172 |
| Ureteral involvement | |
| Positive | 100 |
| Negative | 87 |
| Surgical margins | |
| Positive | 21 |
| Negative | 166 |
| Lymphovascular invasion | |
| Positive | 65 |
| Negative | 122 |
| History of bladder cancer | |
| Present | 47 |
| Absent | 140 |
| CIS | |
| Present | 22 |
| Absent | 165 |
| Hydronephrosis | |
| Positive | 112 |
| Negative | 75 |
| Postoperative recurrence or metastasis | |
| Positive | 53 |
| Negative | 134 |
| Surgical procedure | |
| Open | 104 |
| Laparoscopic | 83 |
| eGFR | |
| <60 | 99 |
| ≥60 | 88 |
| CAR | |
| ≥0.079 | 68 |
| <0.079 | 119 |
| NLR | |
| ≥2.035 | 119 |
| <2.035 | 67 |
| PLR | |
| ≥165 | 63 |
| <165 | 123 |
| GPS | |
| ≥1 | 163 |
| 0 | 24 |
| Fibrinogen (n=146) | |
| ≥337 | 45 |
| <337 | 101 |
UC, urothelial carcinoma; PUNLMP, papillary urothelial neoplasm of low malignant potential; CIS, carcinoma in situ; eGFR, estimated glomerular filtration rate (ml/min/1.73 m2); CAR, C-reactive protein to albumin ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; GPS, Glasgow prognostic score.